Form 8-K - Current report:
SEC Accession No. 0001193125-24-038534
Filing Date
2024-02-16
Accepted
2024-02-16 16:46:54
Documents
14
Period of Report
2024-02-16
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d756154d8k.htm   iXBRL 8-K 38383
  Complete submission text file 0001193125-24-038534.txt   162983

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cere-20240216.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cere-20240216_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cere-20240216_pre.xml EX-101.PRE 11261
15 EXTRACTED XBRL INSTANCE DOCUMENT d756154d8k_htm.xml XML 3650
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39311 | Film No.: 24649107
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)